Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Increases By 8.5%

Atyr PHARMA INC (NASDAQ:ATYR) was the recipient of a large increase in short interest in January. As of January 31st, there was short interest totalling 3,820,000 shares, an increase of 8.5% from the January 15th total of 3,520,000 shares. Currently, 4.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 820,000 shares, the days-to-cover ratio is currently 4.7 days.

Hedge Funds Weigh In On Atyr PHARMA

Institutional investors and hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. bought a new stake in Atyr PHARMA in the 4th quarter worth $53,093,000. Point72 Asset Management L.P. bought a new stake in Atyr PHARMA in the 4th quarter worth $17,677,000. Tikvah Management LLC bought a new stake in Atyr PHARMA in the 4th quarter worth $8,908,000. Woodline Partners LP bought a new stake in Atyr PHARMA in the 4th quarter worth $6,092,000. Finally, Alyeska Investment Group L.P. bought a new stake in Atyr PHARMA in the 4th quarter worth $4,628,000. Institutional investors own 61.72% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on ATYR shares. Cantor Fitzgerald started coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They set an “overweight” rating on the stock. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a research report on Tuesday, December 10th. Finally, Leerink Partners started coverage on shares of Atyr PHARMA in a report on Tuesday. They set an “outperform” rating and a $16.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Atyr PHARMA currently has a consensus rating of “Buy” and a consensus target price of $18.60.

Atyr PHARMA Price Performance

ATYR stock opened at $3.41 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. Atyr PHARMA has a 52 week low of $1.42 and a 52 week high of $4.22. The firm’s fifty day moving average is $3.55 and its 200 day moving average is $2.82. The firm has a market cap of $286.24 million, a P/E ratio of -3.63 and a beta of 1.10.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.